DRL’S Acquisition of Betapharm
-
Upload
gaytri-aggarwal -
Category
Documents
-
view
214 -
download
15
Transcript of DRL’S Acquisition of Betapharm
![Page 1: DRL’S Acquisition of Betapharm](https://reader030.fdocuments.in/reader030/viewer/2022020101/5526af224a795933048b4605/html5/thumbnails/1.jpg)
THE BETAPHARM ACQUISITION
: DRL’s Inorganic Growth Strategy in Europe
Presented by:Amit BajajAmit ModaniGaurav KumarKanika SehgalNitika SharmaNupur KarnaniPrarthana Malhotra
![Page 2: DRL’S Acquisition of Betapharm](https://reader030.fdocuments.in/reader030/viewer/2022020101/5526af224a795933048b4605/html5/thumbnails/2.jpg)
ABOUT DRL… Founded in 1984 : Dr. Anji Reddy.Became public limited in 1986 and started exporting drugs in the same year.First Indian pharmaceutical co. for out licensing the products.Acquisitions : Cheminor drugs, BMS laboratories UK, Meridian healthcare UK.etcOperated in 5 segments as of 2006.
![Page 3: DRL’S Acquisition of Betapharm](https://reader030.fdocuments.in/reader030/viewer/2022020101/5526af224a795933048b4605/html5/thumbnails/3.jpg)
CASE BRIEFING… Acquisition of Betapharm, the 4th largest
pharmaceutical co. in Germany.
DRL won the deal though it was not the highest bidder.
Benefits to both the companies.
DRL also faced problems a few months later due to legal issues, and shelved its further expansion in Europe.
![Page 4: DRL’S Acquisition of Betapharm](https://reader030.fdocuments.in/reader030/viewer/2022020101/5526af224a795933048b4605/html5/thumbnails/4.jpg)
Betapharm Arzneimittel GMBH
• Founded in 1993 at Augsburg• Acquired by 3i• Product Portfolio• Key Figures• Well defined CSR initiatives
![Page 5: DRL’S Acquisition of Betapharm](https://reader030.fdocuments.in/reader030/viewer/2022020101/5526af224a795933048b4605/html5/thumbnails/5.jpg)
![Page 6: DRL’S Acquisition of Betapharm](https://reader030.fdocuments.in/reader030/viewer/2022020101/5526af224a795933048b4605/html5/thumbnails/6.jpg)
Revenue (2005) 186 million
Average Revenue Growth (2000-05)
26% per annum
Market Share in Germany 3.5% to 4% (approx.)
Position in the German generic market
4th
No. of Employees 370
Key Figures for Betapharm
![Page 7: DRL’S Acquisition of Betapharm](https://reader030.fdocuments.in/reader030/viewer/2022020101/5526af224a795933048b4605/html5/thumbnails/7.jpg)
COMPETITION FOR BETAPHARM
• When the bidding process began, there were four Indian companies;– Wockhardt, – Zydus Cadila,– Ranbaxy, and– Dr Reddy’s.
![Page 8: DRL’S Acquisition of Betapharm](https://reader030.fdocuments.in/reader030/viewer/2022020101/5526af224a795933048b4605/html5/thumbnails/8.jpg)
DRL’S ACQUISITION OF BETAPHARM
• Competition to acquire the firm for:• Marketing Infrastructure• Access to German Market • Intense competition in US• Expansion in other than Indian market
![Page 9: DRL’S Acquisition of Betapharm](https://reader030.fdocuments.in/reader030/viewer/2022020101/5526af224a795933048b4605/html5/thumbnails/9.jpg)
DRL EMERGES AS THE WINNER
•Extensive preparation for clinching the deal•Amount paid for the acquisition - 480 million Euros•Analysts thought it to be a costly deal
![Page 10: DRL’S Acquisition of Betapharm](https://reader030.fdocuments.in/reader030/viewer/2022020101/5526af224a795933048b4605/html5/thumbnails/10.jpg)
BENEFITS to DRL• Immediate presence in the German generic market.• Increase in product portfolio•Scope of leveraging a strategic presence in the European generic market.• Large and mature healthcare market of Germany.• Strong manufacturing infrastructure of Betapharm, well-established distribution channels & relationships with doctors, pharmacists, etc.• Reduction in dependence on the US generic market.• The acquisitions also put DRL in a position to look for more acquisitions of smaller pharmaceutical firms.
![Page 11: DRL’S Acquisition of Betapharm](https://reader030.fdocuments.in/reader030/viewer/2022020101/5526af224a795933048b4605/html5/thumbnails/11.jpg)
BENEFITS to BETAPHARM
• It could cover major ailments• It could utilize Dr. Reddy’s expertise• It could take advantage of Low-cost
manufacturing instead of outsourcing
![Page 12: DRL’S Acquisition of Betapharm](https://reader030.fdocuments.in/reader030/viewer/2022020101/5526af224a795933048b4605/html5/thumbnails/12.jpg)
A RISKY ACQUISITION?
•Acquisition resulted in depletion of cash reserves•Declining sales in US generics market as litigation cost was increasing in US•Pressure of reducing price to 20 to 50% in stagnant market•Difficult to increase market share
![Page 13: DRL’S Acquisition of Betapharm](https://reader030.fdocuments.in/reader030/viewer/2022020101/5526af224a795933048b4605/html5/thumbnails/13.jpg)
THANK YOU